We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





New COVID-19 Mouth Swab Test Can Be Completed On-Premises in 13-25 Minutes Without Laboratory Involvement

By LabMedica International staff writers
Posted on 18 May 2020
GeneMe (Gdańsk, Poland) has developed FRANKD, a fast, scalable and reliable mouth swab test for COVID-19 that is completed on-premises in on average 13-25 minutes with no laboratory involvement. More...


FRANKD requires less time to produce a result than the gold-standard RT-PCR (Reverse Transcriptase Polymerase Chain Reaction) reference test recommended by the World Health Organization. The test uses a patented enzyme rather than the currently scarce reagents used in RT-PCR tests to rapidly produce a definitive and reliable result. The use of a portable machine analyzer to amplify the virus within the sample ensures high test accuracy. Additionally, testing on-premises by trained staff removes delays and the challenge of getting test samples to lab technicians to process.

Individuals use the secure, free Yoti digital ID app to link themselves to their test. With consent, the digital test result is automatically added into the tested person’s Yoti. Individuals can present or share their tamperproof, verified details with other parties in seconds - including their test result - whether in person or online, with a tap of a button or scan of a QR code.

The test has been independently validated with 100% sensitivity and 100% specificity by the Gdańsk University of Technology and European CE regulatory certification is expected by early June. FRANKD is currently in talks with governments and businesses across Europe to roll out millions of tests over the coming months, enabling key industries to test hundreds of thousands of employees daily, to help understand the spread of the virus and to monitor the infection R factor more accurately. FRANKD is scalable with five million monthly tests expected from August. During June and July, FRANKD tests will be processed using hundreds of existing analyzer machines that are able to handle 90 tests every 30 minutes, although GeneMe expects affordable bespoke machines to be available from August.

“We are extremely pleased with the quality of the FRANKD test and the contribution it will make towards the fight against the coronavirus pandemic and its damaging effects on public health and society,” said Dawid Nidzworski Founder and CEO of GeneMe and developer of FRANKD.

Related Links:
GeneMe


Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Portable Electronic Pipette
Mini 96
New
Hemodynamic System Monitor
OptoMonitor
New
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.